KR20180137487A - 재조합 폴리스타틴-fc 융합 단백질 및 듀시엔형 근이영양증 치료에서의 용도 - Google Patents

재조합 폴리스타틴-fc 융합 단백질 및 듀시엔형 근이영양증 치료에서의 용도 Download PDF

Info

Publication number
KR20180137487A
KR20180137487A KR1020187028662A KR20187028662A KR20180137487A KR 20180137487 A KR20180137487 A KR 20180137487A KR 1020187028662 A KR1020187028662 A KR 1020187028662A KR 20187028662 A KR20187028662 A KR 20187028662A KR 20180137487 A KR20180137487 A KR 20180137487A
Authority
KR
South Korea
Prior art keywords
cys
glu
lys
ser
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187028662A
Other languages
English (en)
Korean (ko)
Inventor
안드레아 이스켄더리안
안젤라 더블유. 노튼
추안 셴
클라크 판
Original Assignee
샤이어 휴먼 지네틱 테라피즈 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 샤이어 휴먼 지네틱 테라피즈 인크. filed Critical 샤이어 휴먼 지네틱 테라피즈 인크.
Publication of KR20180137487A publication Critical patent/KR20180137487A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C07K14/4708—Duchenne dystrophy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
KR1020187028662A 2016-03-04 2017-03-03 재조합 폴리스타틴-fc 융합 단백질 및 듀시엔형 근이영양증 치료에서의 용도 Withdrawn KR20180137487A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662303954P 2016-03-04 2016-03-04
US62/303,954 2016-03-04
PCT/US2017/020723 WO2017152090A2 (en) 2016-03-04 2017-03-03 Recombinant follistatin-fc fusion proteins and use in treating duchenne muscular dystrophy

Publications (1)

Publication Number Publication Date
KR20180137487A true KR20180137487A (ko) 2018-12-27

Family

ID=58358939

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187028662A Withdrawn KR20180137487A (ko) 2016-03-04 2017-03-03 재조합 폴리스타틴-fc 융합 단백질 및 듀시엔형 근이영양증 치료에서의 용도

Country Status (14)

Country Link
US (1) US20200247856A1 (https=)
EP (1) EP3423479A2 (https=)
JP (1) JP2019509735A (https=)
KR (1) KR20180137487A (https=)
CN (1) CN109153708A (https=)
AU (1) AU2017228475A1 (https=)
BR (1) BR112018067747A2 (https=)
CA (1) CA3016576A1 (https=)
EA (1) EA201891990A1 (https=)
IL (1) IL261397A (https=)
MA (1) MA43588A (https=)
MX (1) MX2018010470A (https=)
SG (1) SG11201807400TA (https=)
WO (1) WO2017152090A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110914294A (zh) * 2017-05-12 2020-03-24 夏尔人类遗传性治疗公司 重组卵泡抑素-fc融合蛋白及其在治疗杜氏肌营养不良中的用途
WO2019118806A1 (en) 2017-12-14 2019-06-20 Solid Biosciences Inc. Non-viral production and delivery of genes
CN108303860B (zh) * 2018-03-26 2019-11-08 西安电子科技大学 一种用于无掩模光刻扫描的分布式曝光方法
WO2019191204A1 (en) * 2018-03-28 2019-10-03 Acceleron Pharma Inc. Follistatin polypeptides for the treatment of muscle contracture
KR20210121137A (ko) * 2019-01-29 2021-10-07 샤이어-엔피에스 파마슈티칼즈, 인크. 부갑상선 호르몬 변이체
CN119343367A (zh) 2022-06-15 2025-01-21 Ucb生物制药有限责任公司 卵泡抑素融合蛋白
US20260049114A1 (en) 2022-06-15 2026-02-19 UCB Biopharma SRL Fusion protein for the prevention, treatment or amelioration of kidney diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
EP1572909A4 (en) * 2002-02-21 2007-06-06 Wyeth Corp PROTEIN CONTAINING A DOMAINE OF FOLLISTATIN
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
WO2008030367A2 (en) * 2006-09-01 2008-03-13 The General Hospital Corporation Selective myostatin inhibitors
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
ES2692268T5 (en) * 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
HK1209034A1 (en) * 2012-06-21 2016-03-24 Indiana University Research And Technology Corporation Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
PL2935320T3 (pl) * 2012-12-18 2020-03-31 Novartis Ag Stabilizowane polipeptydy insulinopodobnego czynnika wzrostu
ES2715710T3 (es) * 2013-01-25 2019-06-05 Shire Human Genetic Therapies Folistatina en el tratamiento de la distrofía muscular de Duchenne
WO2014187807A1 (en) * 2013-05-21 2014-11-27 Arcarios B.V. Follistatin derivatives
EA202090632A1 (ru) * 2014-06-04 2020-07-31 Акселерон Фарма Инк. Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов

Also Published As

Publication number Publication date
MX2018010470A (es) 2018-12-06
EP3423479A2 (en) 2019-01-09
WO2017152090A2 (en) 2017-09-08
SG11201807400TA (en) 2018-09-27
MA43588A (fr) 2021-06-02
US20200247856A1 (en) 2020-08-06
AU2017228475A1 (en) 2018-09-13
CN109153708A (zh) 2019-01-04
BR112018067747A2 (pt) 2019-01-08
CA3016576A1 (en) 2017-09-08
WO2017152090A3 (en) 2017-10-19
IL261397A (en) 2018-10-31
JP2019509735A (ja) 2019-04-11
EA201891990A1 (ru) 2019-04-30

Similar Documents

Publication Publication Date Title
JP6475639B2 (ja) デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン
KR20180137487A (ko) 재조합 폴리스타틴-fc 융합 단백질 및 듀시엔형 근이영양증 치료에서의 용도
CN110914294A (zh) 重组卵泡抑素-fc融合蛋白及其在治疗杜氏肌营养不良中的用途
JP6469022B2 (ja) デュシェンヌ型筋ジストロフィーの治療における抗−ｆｌｔ−１抗体
US10729746B2 (en) Recombinant placenta growth factor for treating Duchenne muscular dystrophy
HK1213804B (zh) 治疗杜兴氏肌营养不良的卵泡抑素
HK1217637B (en) Follistatin in treating duchenne muscular dystrophy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181004

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination